Why it matters. This is a frontier of human gene editing that could one day prevent inherited disease before birth — but the same tool raises the prospect of genetically selected children, a line scientists worldwide consider dangerous to cross.
Background. South Korea is a major and well-funded player in biotechnology; the Institute for Basic Science (IBS) is a national research agency created to boost the country's basic science, and Seoul National and Korea University are two of its most prominent schools. The field carries a long shadow from 2018, when Chinese scientist He Jiankui created the world's first gene-edited babies using cruder CRISPR cutting, was internationally condemned, and was jailed for three years for illegal medical practice.
What to watch next. Researchers will try to eliminate mosaicism and off-target edits, but any clinical use remains years away and faces unresolved global ethical and regulatory barriers.
A safer way to edit human embryos
An international research team from the United States and South Korea has reported the first demonstration of meaningfully safe gene editing in human embryos, using a precision technique to correct disease-linked genes without the chromosomal damage that plagued earlier methods. The findings were posted to bioRxiv, an open repository for biology research that has not yet been peer-reviewed.
The work was led by Professor Dieter Egli at Columbia University in New York, alongside scientists from Seoul National University, Korea University, and South Korea’s Institute for Basic Science (IBS), a government-funded national research body. Their tool is a second-generation technology called base editing, which the team used on single-cell human embryos.
Changing one letter, not cutting the page
First-generation CRISPR-Cas9 gene editing works by slicing through both strands of the DNA double helix at a target site. That cut can cause unintended damage, including lost or broken chromosomes. Base editing avoids cutting entirely. The version used here, an adenine base editor (ABE), simply converts one of DNA’s four chemical letters — adenine (A) — into guanine (G). If a genome were a book, the team changed a single letter rather than tearing out a word.
The researchers corrected three disease-related targets: PCSK9, linked to high LDL (“bad”) cholesterol and heart disease, and HBG1 and HBG2, tied to inherited blood disorders such as sickle cell disease and thalassemia. Detailed analysis found none of the chromosomal losses or fragmentation common with older CRISPR tools.
A key breakthrough was solving why earlier edited embryos kept dying at the 1-to-4-cell stage. The team discovered that the messenger RNA used to deliver the editor was being treated as a foreign invader, halting growth. By instead injecting a pre-assembled protein-RNA complex (RNP), they let embryos develop normally to the roughly 100-to-150-cell blastocyst stage — the point just before a womb would implant. Yale obstetrics professor Emre Seli told Nature the study marked “a conceptual shift” that advanced the field.
Still far from the clinic
The method remains imperfect. Its biggest obstacle is “mosaicism” — only 50 to 75 percent of an embryo’s cells were corrected, leaving the rest unchanged, with some off-target mutations also seen. A person grown from such an embryo could carry different genetic instructions in different parts of the body, with unpredictable effects. Egli said the procedure cannot be used clinically because it could still harm embryos.
The designer-baby debate returns
The study has reopened a fierce bioethics dispute. The fear is that the same tool could move beyond curing disease toward “designer babies” — children selected by parents for looks or intelligence. Stanford bioethicist Hank Greely warned that anyone with a few million dollars could set up an IVF lab and crudely imitate the technique, risking sick children. UC Berkeley’s Fyodor Urnov noted that medicine already screens embryos for disease via preimplantation genetic diagnosis, arguing the new hype mainly empowers those seeking “better” babies.
Adding to the controversy, Science reported that embryo-testing firms accused of pushing designer-baby selection assisted the research: Genomic Prediction provided free DNA sequencing, while Nucleus Genomics — which ran a New York subway ad reading “have the best baby” — plans to fund future testing.
